drugset / Trial / NCT06078592

Comparison of Efficacy and Ocular Surface Assessment Between BRIDIN-plus and Combigan in Glaucoma or Ocular Hypertensive

NCT06078592

Phase 4 Completed 60 enrolled CHA University Hanlim Pharm. Co., Ltd. · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

Comparison of Efficacy and Ocular Surface Disease Assessment between BRIDIN-plus Eye drops and Combigan Eye drops in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control, Randomized, Multi-center Trial

Timeline

Start
2021-10-08
Primary completion
2022-12-23
Completion
2022-12-23

Drugs

EvaluationDrugModalityDoseRoute
Comparator Brimonidine Small molecule 2 mg Topical
Comparator Timolol Other / unclassified 6.8 mg Topical